Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Int131. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 20/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Int131 SCHEMBL634767 | 0.93 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL30035369 | 0.93 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL29404335 | 0.93 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL635008 | 0.92 | PPARG (0.98) | PPARGCYP3A4 | |
| SCHEMBL4468243 | 0.88 | PPARG (0.74) | PPARGCYP3A4 | |
| SCHEMBL24268600 | 0.86 | PPARG (0.87) | PPARGCYP3A4 | |
| SCHEMBL22515346 | 0.86 | PPARG (0.87) | PPARGCYP3A4 | |
| SCHEMBL22203939 | 0.86 | PPARG (0.83) | PPARGCYP3A4 | |
| SCHEMBL22515271 | 0.85 | PPARG (0.84) | PPARGCYP3A4 | |
| SCHEMBL7996313 | 0.84 | PPARG (0.83) | PPARGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677797-B1 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN INC (US) | 2012-02-22 | — | — | EP | claimed |
| EP-1677797-A4 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN INC (US) | 2009-03-25 | — | — | EP | claimed |
| EP-1677797-A2 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | Amgen Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050143416-A1 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. | 2005-06-30 | — | — | US | claimed |
| WO-2005033074-A2 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN, INC. (US) | 2005-04-14 | — | — | WO | claimed |
| EP-2618827-B1 | ANTIDIABETIC SOLID PHARMACEUTICAL COMPOSITIONS | INTEKRIN THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20170273969-A1 | Antidiabetic Solid Pharmaceutical Compositions | INTEKRIN THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9675603-B2 | Solid pharmaceutical compositions of ppary modulator | INTEKRIN THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20130245024-A1 | Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity | LANFEAR DENNIS (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243865-A1 | Antidiabetic Solid Pharmaceutical Compositions | Intekrin Therapeutics, Inc., INC. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2618827-A2 | ANTIDIABETIC SOLID PHARMACEUTICAL COMPOSITIONS | Intekrin Therapeutics, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012040082-A2 | ANTIDIABETIC SOLID PHARMACEUTICAL COMPOSITIONS | INTEKRIN THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2010040055-A2 | ORAL PHARMACEUTICAL FORMULATIONS FOR ANTIDIABETIC COMPOUNDS | INTEKRIN THERAPEUTICS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009111078-A2 | COMBINATION OF A PPARY AGONIST AND A DIPEPTIDYL PEPTIDASE-INHIBITOR FOR THE TREATMENT OF DIABETES AND OBESITY | INTEKRIN THERAPEUTICS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1677797-A4 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070293536-A1 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. | 2007-12-20 | — | — | US | disclosed |
| US-7223761-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1677797-A2 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | Amgen Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050143416-A1 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2005033074-A2 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273969-A1 | Antidiabetic Solid Pharmaceutical Compositions | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 222/4885 |
| US-20070293536-A1 | Salts and polymorphs of a potent antidiabetic compound | PPARD, PPARA, PPARG | PPARG 3/4885CYP3A4 539/4885 |
| US-20050143416-A1 | Salts and polymorphs of a potent antidiabetic compound | PPARD, PPARA, PPARG | PPARG 3/4885CYP3A4 539/4885 |
| US-20130243865-A1 | Antidiabetic Solid Pharmaceutical Compositions | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 248/4885 |
| US-20130245024-A1 | Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity | DPP4, DPP3, DPP7 | PPARG 8/4885CYP3A4 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.